Abstract 610P
Background
The ESMO-MCBS is a valuable tool for the systematic evaluation of clinical benefit of trials. We investigated the applicability of the MCBS in phase 3 trials presented at a major international conference.
Methods
We assessed phase 3 metastatic solid tumor trials presented at ASCO22 which completed recruitment. We included data from the abstract and/or prior and/or subsequent full publication (until March 24th, 2023). MCBS v1.1 evaluation form 2A, 2B, 2C and 3 were used. Preliminary scores were based on overall survival (OS), progression-free survival, and overall response rate, and adjusted according to the pre-specified criteria of the respective evaluation form to reach a final score. Abstracts pertaining to the same study were graded only once and those with subgroups were ranked using the subgroup with the highest score. Grading was performed by three independent reviewers. Discrepancies were resolved through consensus discussion. According to the MCBS, trials scoring ≥ 4 were considered to have meaningful clinical benefit.
Results
Fifty-five phase 3 trials were evaluated, of which 5 could not be scored due to an ungradable endpoint, insufficient or immature data. Of the remaining 50 trials, 9 could not be graded due to statistically non-significant results. The remaining 41 trials were scored based on previous (n=10), subsequent publication (n=14), both (n=1) or abstract only (n=16). Thirteen preliminary scores were adjusted. A meaningful clinical benefit was seen in 21 of 41 trials (51%). Table: 610P
Score | Number of trials | ||
Preliminary scoring (before adjustment) | Final scoring (after adjustment) | Reasons for adjustment to reach final score | |
5 | 0 | 3 | Decreased toxicity (n=1, score +1) Improved quality of life (n=2, score +1) |
4/A | 0 | 2 | Long-term OS benefit (n=2, score +1) |
4 | 20 | 16 | Survival plateau (n=1, score +1) Improved quality of life (n=1, score +1) |
3 | 17 | 12 | Increased toxicity (n=1, score -1) |
2 | 1 | 6 | Improved quality of life (n=1, score +1) Increased toxicity (n=2, score -1) OS not significant (n=2, score -1) |
1 | 3 | 2 | / |
Total | 41 |
Conclusions
Overall, half of the phase 3 trials presented at ASCO22 showed a meaningful clinical benefit using the MCBS. A substantial number of trials could not get a score due to statistically non-significant results; it may be helpful to include these in a modified scale to give a more accurate picture of the clinical value these trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Segelov: Non-Financial Interests, Personal, Member: ESMO-MCBS Working Group. All other authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract